Addition of 2 μg of the antibody, blocked the effect of CRH-treated ovarian cancer cells on PBL apoptosis (6±2% apoptotic PBL in TUNEL and 7±3% in poly-caspase assay for co-cultures with OvCa3, 7±1% in TUNEL and 7±3% in poly-caspase for co-cultures with A2780) (Figures 4F, G and 5F, G). This evidence concerns the gene CRH and ovarian carcinoma.